FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review

Trial Details

NCT ID
NCT06393816
Phase
PHASE2
Sponsor
Centre Leon Berard
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Durvalumab with etoposide and Carboplatin/Cisplatin
Locations (sample)
  • Aix-en-Provence, France|43.5283,5.44973
  • Amiens, France|49.9,2.3
  • Angers, France|47.47156,-0.55202
  • Avignon, France|43.94834,4.80892
  • Brest, France|48.39029,-4.48628

Key Eligibility Criteria

  • Age ≥ 18 years at the time of study entry;
  • Locally documented histological diagnosis of Large-Cell NeuroEndocrine Carcinoma of the lung (2021 WHO classification of Lung Tumors );
  • Patient must have sufficient material to achieve central histological confirmation and exploratory analyses (1 representative FFPE block or at leas…
  • Setting of the disease: locally advanced (Stage III) not eligible for loco-regional therapy or metastatic (Stage IV) in first line treatment (8th T…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →